As previously disclosed, ADMA Biologics, Inc. (NasdaqGM:ADMA) has engaged Morgan Stanley (NYSE:MS) as an advisor to evaluate a variety of strategic and financing alternatives. The evaluation of these alternatives as well as the formal engagement with Morgan Stanley demonstrate ADMA's management and Board of Directors' unwavering commitment to creating value for its stockholders. Further, ADMA continues to actively engage prospective debt lenders to potentially refinance and expand ADMA's current debt facility.

These concurrent processes are ongoing, and the Company will communicate developments as they unfold and as required by the Securities and Exchange Commission.